Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan") resulted in an increase in the notional allocation of Ordinary Share ADRs on July 14, 2006. The transaction occurred at a price of $54.07 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: July 14, 2006 (Notification date: July 18, 2006).
- Transaction Price: $54.07 per Ordinary Share ADR.
- Involved Parties: Dr. M. M. Slaoui (8 shares) and Dr. R. Greig (2 shares).
- Plan Details: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs.